Brookstone Capital Management Purchases 154,286 Shares of Pfizer Inc. $PFE

Brookstone Capital Management increased its position in shares of Pfizer Inc. (NYSE:PFE) by 134.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 269,381 shares of the biopharmaceutical company’s stock after acquiring an additional 154,286 shares during the period. Brookstone Capital Management’s holdings in Pfizer were worth $6,864,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the company. Value Partners Investments Inc. bought a new stake in Pfizer during the third quarter worth $4,177,000. Alliance Wealth Advisors LLC lifted its position in shares of Pfizer by 2.4% during the 3rd quarter. Alliance Wealth Advisors LLC now owns 24,304 shares of the biopharmaceutical company’s stock worth $619,000 after buying an additional 562 shares during the last quarter. Gilman Hill Asset Management LLC boosted its stake in Pfizer by 2.0% in the third quarter. Gilman Hill Asset Management LLC now owns 410,188 shares of the biopharmaceutical company’s stock valued at $10,452,000 after buying an additional 8,109 shares in the last quarter. Swedbank AB boosted its stake in Pfizer by 6.0% in the third quarter. Swedbank AB now owns 4,862,888 shares of the biopharmaceutical company’s stock valued at $123,906,000 after buying an additional 276,059 shares in the last quarter. Finally, Vontobel Holding Ltd. grew its position in Pfizer by 13.0% in the third quarter. Vontobel Holding Ltd. now owns 831,628 shares of the biopharmaceutical company’s stock valued at $21,190,000 after acquiring an additional 95,393 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on PFE shares. BMO Capital Markets reissued an “outperform” rating on shares of Pfizer in a report on Wednesday, December 10th. Citigroup initiated coverage on shares of Pfizer in a research note on Tuesday, December 2nd. They issued a “neutral” rating and a $26.00 price objective for the company. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. Scotiabank initiated coverage on shares of Pfizer in a report on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 price target for the company. Finally, Sanford C. Bernstein reiterated a “market perform” rating and issued a $30.00 price target on shares of Pfizer in a research note on Friday, October 31st. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $28.06.

Pfizer Trading Up 0.3%

Shares of NYSE PFE opened at $25.10 on Friday. The firm has a 50 day moving average price of $25.16 and a two-hundred day moving average price of $24.89. The stock has a market cap of $142.68 billion, a P/E ratio of 14.59 and a beta of 0.46. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $27.69. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, topping analysts’ consensus estimates of $0.79 by $0.08. The company had revenue of $16.65 billion for the quarter, compared to analyst estimates of $16.94 billion. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.9%. The ex-dividend date is Friday, January 23rd. Pfizer’s dividend payout ratio (DPR) is 100.00%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.